Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
  • 0 views
  • 26 Jan, 2021
  • 1 location
DORA: The Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV in South Africa

reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy on metabolic and neuropsychiatric outcomes.

  • 0 views
  • 26 Jan, 2021
  • 2 locations
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

DEFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir

ritonavir
antiretroviral therapy
dolutegravir
antiretroviral agents
antiretroviral
  • 1172 views
  • 25 Mar, 2021
  • 32 locations
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

This study will evaluate the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT is given with isoniazid (INH) daily for 4 weeks (1HP) as part

western blot
immune globulin
urine test
hysterectomy
total bilirubin
  • 0 views
  • 23 Jun, 2021
  • 6 locations
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase

immunodeficiency
dolutegravir
lamivudine
antiviral drugs
integrase inhibitors
  • 188 views
  • 27 Jan, 2021
  • 15 locations
The Pharmacokinetics Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

The purpose of this study is to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in HIV-1-infected children

immune globulin
hysterectomy
lamivudine
antiretroviral agents
atazanavir
  • 30 views
  • 24 May, 2021
  • 14 locations
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

investigate the safety, efficacy and dose-response of GSK3640254 compared to dolutegravir (DTG), each given in combination with 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (abacavir/lamivudine [ABC

  • 0 views
  • 23 Jun, 2021
  • 48 locations
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the …

  • 0 views
  • 25 Jan, 2021
  • 16 locations
Contribution of Dolutegravir to Obesity and Cardiovascular Disease

The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued

  • 0 views
  • 02 Feb, 2021
  • 1 location
  • 0 views
  • 23 Jan, 2021
  • 1 location